Story preview
Topics in this story
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
4
in the last 3 days
First reported
4 days ago
3 outlets since
Countries
3 other outlets reported this story in the last 3 days.
Cantor Fitzgerald said the positive panel outcome materially improves the chances of accelerated approval for Replimune's RP1 therapy ahead of the Aug. 2 FDA decision.
VUSA, VUAG and CSP1 all track the S&P 500 at a 0.07% charge. See how dividends, currency exposure and ISA rules differ for UK investors.